Leslie L. Citrome, MD, MPH

January 21, 2021

The first-and-only transdermal patch for adults with schizophrenia offers a new treatment.

October 04, 2019

P values tell half of the story. A result that is statistically significant may actually be clinically irrelevant. More in this video.

October 03, 2019

P values can be deceiving. In order to determine if a clinical trial result is important, we need to look at the effect size.

September 14, 2017

Schizophrenia and T2 DM risk; short-term weight gain with specific antipsychotics; interventions to reduce weight and/or metabolic abnormalities. . .answers here.

September 03, 2014

A video summarizing key points of a presentation titled “Agitation and Aggression: Managing the Acute Episode and Beyond, An Evidence-Based Approach.”

September 26, 2013

How can you apply the framework and philosophy of evidence-based medicine to the use of antipsychotic medication? Here to discuss is Leslie L. Citrome, MD, MPH.

April 02, 2012

Several studies have been undertaken to test the efficacy of drugs in the management of aggression and hostility in patients with schizophrenia and other mood disorders.

January 09, 2010

CATIE can be viewed as a switch study. Switches offer both opportunity and risk. Data from CATIE demonstrate differences in overall effectiveness, but these differences depend on the individual patient context.

May 01, 2003

Increasing variations in mechanisms of action of atypical antipsychotics, side-effect profiles, and efficacy among the atypicals enable clinicians to tailor treatments to individual response, side-effect history, and current medical conditions.